Bijal Shah, MD, Moffit Cancer Center

Articles

Dr. Shah on Efforts to Combat Resistance to BTK Inhibitors in MCL

July 7th 2021

Bijal Shah, MD, MS, discusses efforts to combat resistance to BTK inhibitors in patients with mantle cell lymphoma.

Dr. Shah on Shortcomings With BTK Inhibitors in High-Risk MCL

June 3rd 2021

Bijal Shah, MD, MS, discusses shortcomings with BTK inhibitors in high-risk mantle cell lymphoma.

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

March 4th 2021

Evolving Field of Acute Lymphoblastic Leukemia

March 4th 2021

Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

February 25th 2021

CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

February 25th 2021

CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia

February 18th 2021

Approach to Managing Relapsed Acute Lymphoblastic Leukemia

February 18th 2021

Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

February 11th 2021

Managing MRD-Negative Acute Lymphoblastic Leukemia

February 11th 2021

Managing MRD-Positive Acute Lymphoblastic Leukemia

February 4th 2021

Treatment of Acute Lymphoblastic Leukemia in the Community Setting

February 4th 2021

Role of MRD Testing in Acute Lymphoblastic Leukemia

January 28th 2021

Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

January 28th 2021

Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

January 21st 2021

Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

January 13th 2021

Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

January 13th 2021

Prognostic Factors Which Impact ALL Management

January 13th 2021

Dr. Shah on Results of ZUMA-3 Study for ALL

June 26th 2019

Bijal Shah, MD, discusses the results of the phase I/II ZUMA-3 study, which looked at using KTE-X19, an anti-CD19 CAR T-cell therapy, to treat patients with relapsed/refractory acute lymphoblastic leukemia.